Helpline 07939 046 030

Research Outlook with Prof Gareth Evans

09 April 2019

Prof Gareth Evans is the Chair of the Medical Advisory Board of Nerve Tumours UK, and has an established international reputation in the treatment and research of Neurofibromatosis. Here he gives a brief overview of the current research landscape for NF.

Research Outlook with Prof Gareth Evans

Prof Gareth Evans is the Chair of the Medical Advisory Board of Nerve Tumours UK, and has an established international reputation in the treatment and research of Neurofibromatosis. Here he gives a brief overview of the current research landscape for NF.

There is very little funded research in the UK – the research in the UK which is published is rarely fully funded. We are reliant for the most part on developments in the US, which is underpinned by around $15m a year in grants from the US Department of Defense.


The most hopeful developments are in drug treatments, MEK Inhibitors for NF1, and Avastin for NF2 (each described below). I am hopeful that these drug treatments will become mainstays in UK treatment.

NF2: Avastin

Extract from Addenbrooke’s Hospital, Cambridge:

Avastin is a type of drug treatment known as antiangiogenic therapy. It works by blocking signals made by tumours that cause blood vessels to grow in their vicinity. Without the
support of blood vessels, the tumour lacks nutrients and oxygen needed to grow. The NHS national programme for Avastin therapy for NF2 patients has been running since 2010. The
latest evaluation shows that in 90% of patients the tumour either shrinks or stops growing and hearing function either stabilises or improves in 86% of patients.

Extract from Oxford University Hospitals’ information guide:

Avastin is given to people with NF2 when a schwannoma has grown by a specific amount or more over the previous year. The schwannoma will be measured by looking at and comparing
MRI scans over the course of a year. Evidence suggests that Avastin is more effective in faster growing tumours. National guidelines state that patients need to have schwannomas that meet the specific growth rate criteria for them to be considered for treatment with Avastin.

Avastin is given for the treatment of NF2 initially for six months, with three monthly MRI scans and clinic reviews. If a tumour starts to grow despite having Avastin treatment, then the drug will be stopped. The drug will also be stopped if you suffer significant side effects.

"The latest evaluation shows that in 90% of patients the tumour either shrinks or stops growing"

– Prof Gareth Evans

NF1: MEK Inhibitors

Neurofibromin is the protein which is downstream of the NF1 gene, and suppresses the proliferation of
tumours. It is its absence that causes tumours for people with NF1. The way that MEK Inhibitors work has been helpfully described by Dr Annette Bakker, President and Chief Scientific Officer of the Children’s Tumor Foundation, in the US. She uses the analogy of an unruly classroom, where neurofibromin is the teacher who normally keeps control, but is absent. MEK is the naughtiest child in the class, who causes most of the trouble in the absence of the teacher. The MEK Inhibitor drug keeps that naughty child under control.

Subcutaneous neurofibroma (left hand): X-ray and photograph

A study by French researchers reported in ecancermedicalscience, showed dramatic results in a 12-year-old boy with NF1, who was finding walking impossible, and suffering increased pain in his hand (see images on the right). Within a week of beginning treatment with a MEK Inhibitor, Trametinib, he was walking again, and the pain had disappeared. These results were sustained, and after a year, he no longer needed to take the drug.

MEK Inhibitors are currently undergoing clinical trials in the US, and are showing similarly ‘spectacular’ results. The Children’s Tumor Foundation are hopeful they will soon be approved
for patient treatment.

"Within a week of beginning treatment with a MEK Inhibitor, Trametinib, he was walking again, and the pain had disappeared."

– Prof Gareth Evans

Filter News

Filter by Date
Category
Reset

Carers Rights Day. Diane’s Story

Find out more about Diane's life as a carer and how more should be done for unpaid carers in the UK

Read More

Sarah’s Story

Sarah has NF1 and works full time for the NHS check out her intriguing story here

Read More

Ella’s editorial

Have a read of Ella's editorial as she shares her brave journey against NF1 with us!

Read More

Visible Difference Equality Law Research: summary of findings

Find out more about the results here:

Read More

The Galloway Family and their “amazing” four year old Ruby

Have a read about the incredibly brave young Ruby Galloway (NF1) and check out their previous and future fundraiers.

Read More

“Framing the face: History, Emotion, Transplantation” a blog from James Partridge

Find out more about the blog and what is concerns here:

Read More

A Spooktacular Halloween day for NTUK

Find out more about the wonderful fundraising event here:

Read More

Nicks Triathlon in Support of his daughter Eilidh

Find out more about Nick's Triathlon and his daughter's experiences with NF1 here:

Read More

An Adolescent Support Day for teenagers with NF1

Bridie Windsor is a Deputy Clinical Nurse Specialist who has organised a support day for teenagers with NF1. Read more here:

Read More